12:00 AM
May 25, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AMG 655: Interim Phase Ib/II data

Interim data from the ongoing Phase Ib/II trial in 15 patients showed that 10 mg/kg AMG 655 in combination with 6 mg/kg Vectibix panitumumab did not cause any DLTs after a median follow-up of...

Read the full 157 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >